Drug – bio-affecting and body treating compositions – Lymphokine
Reexamination Certificate
2005-09-13
2005-09-13
Celsa, Bennett (Department: 1639)
Drug, bio-affecting and body treating compositions
Lymphokine
C514S002600, C514S012200, C530S300000, C530S324000
Reexamination Certificate
active
06942852
ABSTRACT:
N-terminally modified RANTES derivatives are disclosed. The derivatives effectively block the inflammatory effects of RANTES, and are useful for the treatment of asthma, allergic rhinitis, atopic dermatitis, atheroma/atherosclerosis, and rheumatoid arthritis. Additionally, the compounds are useful for the treatment of HIV infection.
REFERENCES:
patent: 5122614 (1992-06-01), Zalipsky
patent: 5672662 (1997-09-01), Harris et al.
patent: 5739208 (1998-04-01), Harris
patent: 6168784 (2001-01-01), Offord et al.
patent: 0 605 963 (1993-12-01), None
patent: 96/17935 (1996-06-01), None
patent: 96/34878 (1996-11-01), None
Rudinger, Peptide Hormones (Ed. J. Parsons, Jun. 1976) pp. 1-6.
Abuchowski, Abraham, et al., “Alteration of Immunological Properties of Bovine Serum Albumin by Covalent Attachment of Polyethylene Glycol”,J. Biol. Chem., vol. 252, No. 11, pp. 3578-3581 (1977).
Alkhatib, Ghalib, et al., “CC CKR5: A RANTES, MIP-1α, MIP-1β Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1”,Science, vol. 272, pp. 1955-1958 (1996).
Angiolillo, et al., “A Role for the Interferon-Inducible Protein 10 in Inhibition of Angiogenesis by Interleukin-12”,Annals NY Acad. Sci., vol. 795, pp. 158-167 (1996).
Arenzana-Seisdedos, Fernando, et al., “HIV Blocked by Chemokine Antagonist”,Nature, vol. 383, p. 400 (1996).
Berger, et al., “A New Classification for HIV-1”,Nature, vol. 391, p. 240 (1998).
Cairns, et al., “Chemokines and HIV-1 Second Receptors: The Therapeutic Connection”,Nature Med., vol. 4, No. 5, pp. 563-568 (1998).
Chen, et al., “Genetically Divergent Strains of Simian Immunodeficiency Virus Use CCR5 as a Co-Receptor for Entry”,J. Virol., vol. 71, No. 4, pp. 2705-2714 (1997).
Chesebro, et al., “Mapping of Independent V3 Envelope Determinants of Human Immunodeficiency Virus Type 1 Macrophage Tropism and Syncytium Formation in Lymphocytes”,J. Virol., vol. 70, No. 12, pp. 9055-9059 (1996).
Choe, et al., “The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates”,Cellvol. 85, pp. 1135-1148 (1996).
Cocchi, et al., “Identification of RANTES, MIP-1α, and MIP-β as the the Major HIV-Suppressive Factors Produced by CD8+ T Cells”,Science, vol. 270,pp. 1811-1815 (1995).
Cocchi, et al., “The V3 Domain of the HIV-1 gp 120 Envelope Glycoprotein is Critical for Chemokine-Mediated Blockade of Infection”,Nature Med., vol. 2, No. 11, pp. 1244-1247 (1996).
Connor, et al., “Increased Viral Burden and Cytopathicity Correlate Temporally with CD4+ T-Lymphocyte Decline and Clinical Progression in Human Immunodeficiency Virus Type 1-Infected Individuals”,J. Virol., vol. 67, No. 4, pp. 1772-1777 (1993).
Danesi, et al., “Inhibition of Experimental Angiogenesis by the Somatostatin Analogue Octretide Acetate (SMS 201-995)1”,Clin. Cancer Res., vol. 3, pp. 265-272 (1997).
Datema., et al., “Antiviral Efficacy in Vivo of the Anti-Human Immunodeficiency Virus Bicyclam SDZ SID 791 (Jm3100), an Inhibitor of Infectious Cell Entry”,Antimicrob. Agents and Chemo., vol. 40, No3., pp. 750-754 (1996).
Dawson, et al., “Synthesis of Proteins by Native Chemical Ligation”,Science, vol. 266, pp. 776-779 (1994).
Deng, et al., “Identification of a Major Co-Receptor for Primary Isolates of HIV-1”,Nature, vol. 381, pp. 661-666 (1996).
Doranz, et al., “A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3, and CKR-2B as Fusion Cofactors”,Cell, vol. 85, pp. 1149-1158 (1996).
Friedlander, et al. “Definition of Two Angiogenic Pathways by Distinct α, Integrins”,Science, vol. 270, pp. 1500-1502 (1995).
Gao, et al., “Structure and Functional Expression of the Human Macrophage Inflammatory Protein 1α/RANTES Receptor”,J. Exp. Med., vol. 177, pp. 1421-1427 (1993).
Gauduin, et al., “Passive Immunization with a Human Monoclonal Antibody Protects hu-PBL-SCID Mice Against Challenge by Primary Isolate of HIV-1”,Nat. Med., vol. 3, No. 12, pp. 1389-1393 (1997).
Hojo, Hironobu and Aimoto, Saburo, “Polypeptide Synthesis Using the S-Alkyl Thioester of a Partially Protected Peptide Segment. Synthesis of the DNA-Binding Domain of c-Myb Protein (142-193)-NH2”,Bull.Chem.Soc.Jpn., vol. 64, pp. 111-117 (1991).
Jose, et al., “Eotaxin: A Potent Eosinophil Chemoattractant Cytokine Detected in a Guinea Pig Model of Allegric Airways Inflammation”,J.Exp.Med., vol. 179, pp. 881-887 (1994).
Mack, et al., “Aminooxypentane-RANTES Induces CCR5 Internalization but Inhibits Recycling: A Novel Inhibitory Mechanism of HIV Infectivity”,J.Exp.Med., vol. 187, No. 8, pp. 1215-1224 (1998).
Mosier, et al., “Transfer of a Functional Human Immune System to Mice With Severe Combined Immunodeficiency”,Nature, vol. 335, pp. 256-259 (1988).
Mosier, et al., “Human Immunodeficiency Virus Infection of Human-PBL-SCID Mice”,Science, vol. 251, pp. 791-794 (1991).
Mosier, et al, “Rapid Loss of CD4+ T Cells in Human-PBL-SCID Mice by Noncytopathic HIV Isolates”,Science, vol. 260, pp. 689-692 (1993).
Mosier, Donald, “Human Immunodeficiency Virus Infection of Human Cells Transplanted to Severe Combined Immunodeficient Mice”,Adv.in Immun., vol. 63, pp. 79-125 (1996).
McKnight, et al., “HIV-2 and SIV Infection of Nonprimate Cell Lines Expressing Human CD4: Restrictions to Replication at Distinct Stages”,Virology, vol. 201, pp. 8-18 (1994).
Neote, et al., “Molecular Cloning, Functional Expression, and Signaling Characteristics of a C-C Chemokine Receptor”,Cell, vol. 72, pp. 415-425 (1993).
Oikawa, et al., “Angiogenic Factor of a rat Mammary Tumor Cell Line (RMT-1) (I). Secretion of two Distinct Angiogenic Factors Into Serum-Free Conditioned Medium by RMT-1 Cells”,Cancer Lett., vol. 59, pp. 57-66 (1991).
Parren, et al., “Protection Against HIV-1 Infection in hu-PBL-SCID Mice by Passive Immunization With a Neutralizing Human Monoclonal Antibody Against the gp120 CD4 Binding Site”, AIDS, vol. 9, No. 6, pp. 1-6 (1995).
Paxton, et al., “Reduced HIV-1 Infectability of CD4+ Lymphocytes From Exposed-Unifected Individuals: Association With Low Expression of CCR5 And High Production of β-Chemokines”,Virology, vol. 244, pp. 66-73 (1998).
Picchio, et al., “Chemokine Receptor CCR5 Genotype Influnces the Kinetics of Human Immunodeficiency Virus Type 1 Infection in Human PBL-SCID Mice”,J. Virol., vol. 71, No. 9, pp 7124-7127 (1997).
Picchio, et al., “The Cell Tropism of Human Immunodeficiency Virus Type 1 Determines the Kinetics of Plasma Viremia in SCID Mice Reconstituted With Human Peripheral Blood Leukocytes”,J.Virol., vol. 72, No. 3, pp. 2002-2009 (1998).
Proudfoot, et al., “Extension of Recombinant Human RANTES by the Retention of the Initiating Methionine Produces a Potent Antagonist”,J.Biol.Chem., vol. 271, No. 5, pp. 2599-2603 (1996).
Risau, Werner, “Mechanisms of Angiogenesis”,Nature,vol. 386, pp. 671-674 (1997).
Schnolzer, et al., “In situ neutralization in Boc-chemistry Solid Phase Peptide Synthesis”,J.Peptide Protein Res., vol. 40, pp. 180-193 (1992).
Schuitemaker, et al., “Monocytotropic Human Immunodeficiency Virus Type 1 (HIV-1) Variants Detectable in all Stages of HIV-1 Infection Lack T-Cell Line Tropism and Syncytium-Inducing Ability in Primary T-Cell Culture”,J. Virol., vol.. 65, No. 1, pp. 356-363 (1991).
Simmons, et al., “Potent Inhibition of HIV-1 Infectivity in Macrophages and Lymphocytes by a Novel CCR5 Antagonist”,Science, vol. 276, pp. 276-279 (1997).
Simmons, et al., “Primary, Syncytium-Inducing Human Immunodeficiency Virus Type 1 Isolates Are Dual-Tropic and Most Can Use Either Lestr or CCR5 as Coreceptors for Virus Entry
Offord Robin E.
Thompson Darren
Wilken Jill
Auerbach Jeffrey
Celsa Bennett
Gryphon Therapeutics, Inc.
Joyce Catherine
Liniak Berenato & White
LandOfFree
N-terminal modifications of RANTES and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-terminal modifications of RANTES and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-terminal modifications of RANTES and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3410420